CQ Researcher provides award winning in-depth coverage of the most important issues of the day. Our reports are written by experienced journalists, footnoted and professionally fact-checked. Full-length articles include an overview, historical background, chronology, pro/con feature, plus resources for additional research. Graphics, photos and short "sidebar" features round out the reports. Shorter "Hot Topics" articles provide a solid introduction to subjects most in demand by students.

Youtube video

FEATURED REPORT

Conquering Rare Diseases

- January 24, 2020
Should taxpayers keep paying to develop drugs for unusual disorders?
Featured Report

More than 30 million Americans suffer from one of 7,000 rare diseases — incurable, often genetic conditions affecting fewer than 200,000 people. There is no treatment for 95 percent of these diseases, in part because pharmaceutical companies have been reluctant to invest in developing drugs for such small potential markets. That began to change after Congress in 1983 created tax incentives and exclusive marketing rights for companies that develop treatments for rare diseases. Since then, more than 700 drugs targeting such conditions have been approved, and about half of all new pharmaceuticals approved in 2018 were for rare diseases. While these treatments, including expensive new gene therapies, save lives and offer patients hope, they often come with high price tags: One drug, a one-time treatment, costs more than $2 million. Some experts and policymakers question whether taxpayers need to continue subsidizing the development of such drugs. Meanwhile, patient advocacy organizations are investing in drug research, participating in clinical trials, sharing data and lobbying for continued government support and investment in treatments for rare diseases.

Expensive Progress

Cut Costs?

 
1960s–1980sGovernment and patients encourage development of “orphan” drugs for rare diseases.
1990sSome orphan drugs begin to generate large profits.
2000sThe biotechnology industry, including companies working on rare disease treatments, enjoys robust growth.
2010sA record-high number of drugs is approved under the Orphan Drug Act.
   

Should company incentives in the Orphan Drug Act be reduced or changed?

Pro

Ben Berger
Ph.D. Candidate in Public Policy, Harvard University.

Con

Peter L. Saltonstall
President and CEO, National Organization for Rare Disorders.

RECENT REPORTS

Supply Chains at Risk
Are tariffs and technology disrupting global trade routes?
Political Polls
Will their accuracy improve in 2020?
Global Migration
Can governments head off another crisis?

HOT TOPICS

Read the latest updates to our most popular topics

UPCOMING REPORTS

Presidential Primaries - 1/31/2020

Does the system produce the strongest nominees?

Hidden Money - 2/7/2020

Can the government outsmart tax evaders?

FEEDBACK